Shorts

$Surbhi Sidana, MD, discussed what implications the approval of teclistamab plus daratumumab among patients with relapsed/refractory multiple myeloma would have on practice for this disease.$

Daratumumab/Teclistamab Multiple Myeloma Approval Could Expand Treatment Options

8 months ago

by

Surbhi Sidana, MD

Nathan Goodyear, MD, touched upon research which might suggest that malignant cancer cells may be able to be transformed back to normal functioning ones.

Could Malignant Cancer Cells Be Transformed Back to Normal Functioning Ones?

8 months ago

by

Nathan Goodyear, MD

Nathan Goodyear, MD, discussed the “restoration” of the patient-doctor relationship in integrative oncology and oncology as a whole brought about by patient demands for a more collaborative relationship.

Restoring the Patient-Doctor Relationship Through Collaboration in Integrative Oncology

8 months ago

by

Nathan Goodyear, MD

Ash Tewari, MBBS, MCh, FRCS, discussed the impact that a mobile prostate cancer testing unit has had on the local community.

Unplanned Mobile Unit Testing Identified Early-Stage Prostate Cancer

8 months ago

by

Ash Tewari, MD, MBBS, MCh, FRCS

In this video, Tewari highlighted developments in nerve-sparing prostate cancer procedures, with a particular emphasis on one that is aimed at preserving erectile function following surgery.

Recovering Sexual Function Through Nerve-Sparing GU Procedures

8 months ago

by

Ash Tewari, MD, MBBS, MCh, FRCS

For this video, Janjigian highlighted the unifying impact of the MATTERHORN trial, which established perioperative immunotherapy among this patient group regardless of location.

Unifying Perioperative Immunotherapy Globally in Gastric Cancer Treatment

8 months ago

by

Yelena Y. Janjigian, MD

Janjigian discussed the role of pathologic complete response rate as an early indicator for cure among patients with gastric cancer, particularly in the absence of long-term survival data.

Pathologic CR Rates May Provide Early Indicator of Cure in Gastric Cancers

8 months ago

by

Yelena Y. Janjigian, MD

Janjigian touched upon key design elements of the MATTERHORN trial, which sought to assess the safety and efficacy of the FLOT-based combination among patients with gastric cancer globally.

Treating Gastric Cancer With “Modern” FLOT Backbone Regardless of PD-L1 Status

8 months ago

by

Yelena Y. Janjigian, MD

In an interview with CancerNetwork®, Nathan Goodyear, MD, discussed the creation of "hot" tumor microenvironment through integrative oncology strategies.

Creating an Immune “Hot” Tumor Microenvironment Through Integrative Oncology

8 months ago

by

Nathan Goodyear, MD

James R. Berenson, MD, outlined the benefits of the text-based monitoring of symptoms and quality of life (mQOL) platform on patient-reported outcomes (PROs) in clinical practice at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition.

Spotlighting a 3-Minute mQOL Questionnaire for PROs in Hematology

9 months ago

by

James R. Berenson, MD, FACP

$Krina K. Patel, MD, MSc, discussed the efficiency of the mechanism of action for anito-cel, which uses a smaller protein to increase the frequency of CAR transductions in patients undergoing treatment for relapsed/refractory multiple myeloma.$

Maximizing CAR T-cell Efficiency in Multiple Myeloma Through the D-Domain

9 months ago

by

Krina K. Patel, MD, MSc

Hannah Goulart, MD, a hematology oncology fellow at the MD Anderson Cancer Center, explained that patients with Ph-positive B-ALL may experience an improvement in QOL with an immunotherapy-based backbone vs a chemotherapy-based backbone.

How Removing Intensive Chemotherapy May Improve QOL in Ph+ B-ALL

9 months ago

by

Hannah Goulart, MD

Charles S. Kamen, PhD, MPH, suggests that clinicians should anticipate a greater sensitivity to cues of rejection among patients that are sexual or gender minorities, which would prompt them to make a greater effort to include a patient’s support people in decision-making processes.

Highlighting Decision-Making Inclusion for LGBTQ+ Loved Ones/Caregivers

9 months ago

by

Charles S. Kamen, PhD, MPH

Charles S. Kamen, PhD, MPH, discussed the prevalence of minority stress, which could emerge in an anticipatory fashion, due to systemic prejudices impacting these patients.

Addressing the Burden of Disclosure for LGBTQ+ Patients in Oncology Care

9 months ago

by

Charles S. Kamen, PhD, MPH

Charles S. Kamen, PhD, MPH, discussed the prevalence of LGBTQ+ individuals in oncology care, as well as navigating difficulties associated with delivering patient-centric care to them.

Practice With Cultural Humility: Treating LGBTQ+ Patients with Cancer

9 months ago

by

Charles S. Kamen, PhD, MPH

Daniel Peters, MD, discussed 3 main pillars he uses to guide practice when treating patients with acute myeloid leukemia (AML); patient health, treatment goals, and molecular testing (genomics).

Guiding AML Treatment Stategy: Three Pillars For Clinicians

9 months ago

by

Daniel Peters, MD

Cary Gross, MD, discussed results from a study he coauthored regarding quality of care outcomes among patients treated with cancer during incarceration or within the year following release. Specifically, he discussed a need for the re-engagement of patients with cancer who were recently released from incarceration in the health care system and programs such as the Transitions Programs, which aim to fulfill that need.

Engaging Patients With Cancer Into Health Care Systems After Incarceration

9 months ago

by

Cary Gross, MD

Thomas Marron, MD, discussed a presentation he gave at the Chemotherapy Foundation Symposium (CFS) titled, "Stage I-III Is Not What It Used to Be".

Immune System Training: Explicating Perioperative Immunotherapy Use

9 months ago

by

Thomas Marron, MD, PhD

Rona Yaeger, MD, discussed key takeaways from her presentation titled, “Targeting BRAF, KRAS, and HER2 in GI Tumors” in an interview at the 43rd Annual Chemotherapy Foundation Symposium (CFS) in New York, NY.

Testing For Mutational Status Might Improve Colorectal Cancer Survival

10 months ago

by

Rona Yaeger, MD

Michael Barish, PhD, discussed the application of a scorpion venom-derived chlorotoxin in treating 4 patients with glioblastoma in an interview with CancerNetwork.

Exploring The Applicability of Scorpion Venom in Glioblastoma Treatment

10 months ago

by

Michael Barish, PhD

Toru Kondo, PhD, discussed his presentation titled, "Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells," that he gave at World ADC

EVA1-Targeting ADCs May Reduce AEs vs Anti-CD133 Agents in Glioblastoma

10 months ago

by

Toru Kondo, PhD

ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings

ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings

10 months ago

by

Aditya Bardia, MD, MPH, FASCO

Patients with medullary thyroid carcinoma or the MEN type 2 genetic disorder should not start GLP-1 agents for risk of insulin secretion and severe hypoglycemia.

When Should Patients with NETs Be Advised Not To Take GLP-1 Agents?

10 months ago

by

Joseph Dillon, MB, BCh, BAO

Micheal C. Soulen, MD, discussed his presentation of the phase 2 CapTemY90 trial assessing the combination of radioembolization and chemotherapy in patients with liver-dominant NETs at the 2025 North American Neuroendocrine Tumor Symposium.

Y90/Radiosensitizing Chemotherapy Regimen Feasible in Liver-Dominnat NETs

10 months ago

by

Michael C. Soulen, MD

In an interview with CancerNetwork®, Eyub Akdemir, MD, radiation oncologist at Miami Cancer Institute, discussed findings from a single-institution retrospective study evaluating the timing and predictors of severe lymphopenia in patients with lung cancer treated with definitive proton chemoradiotherapy.

Proton Chemoradiotherapy May Reduce Severe Lymphopenia Rates

10 months ago

by

Eyub Akdemir, MD

CancerNetwork spoke with Udhayvir S. Grewal, MBBS, assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, about an analysis of the Neuroendocrine Tumors - Patient-Reported Outcomes (NET-PRO) study he presented at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium.

NET-PRO: Younger NET Population Experiences More Significant AEs

10 months ago

by

Udhayvir S. Grewal, MD

CancerNetwork® spoke with Mary Maluccio, MD, MPH, FACS, about her presentation on a PRRT–naive cohort of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received the investigational SSTR–targeted alpha therapy 212Pb-DOTAMTATE at NANETS.

Examining 212Pb-DOTAMTATE Clinical Outcomes in PRRT-Naive GEP-NETs

10 months ago

by

Mary Maluccio, MD, MPH, FACS

According to Stefano Partelli, MD, PhD, quality metrics in pNET surgery are fundamentally tied to the experience and volume of the treating center, given the high risk of complications and mortality.

Predicting Early Post-Surgical Recurrence in pNETs

10 months ago

by

Stefano Partelli, MD, PhD

Julie Hallet, MD, MSc, FRCSC, stated that the core mission of initiatives like CUTNETs is to standardize care and mitigate the high risks associated with complex operations on neuroendocrine tumors.

CUTNETs: Spotlighting a Collaboration Between Surgery and NET Oncology

10 months ago

by

Julie Hallet, MD, MSc, FRCSC

Twelve patients in the CARTITUDE-1 trial maintained a cancer-free, MRD-negative status for 5 years without maintenance, fulfilling a proposed curative definition for a "cure".

Including "Cure" in the Multiple Myeloma Treatment Dialogue

a year ago

by

Sundar Jagannath, MD

Trending on CancerNetwork

Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer

Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA